Protein Summary
Isoform Crk-II: Regulates cell adhesion, spreading and migration. Mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4. May regulate the EFNA5-EPHA3 signaling. This gene encodes a member of an adapter protein family that binds to several tyrosine-phosphorylated proteins. The product of this gene has several SH2 and SH3 domains (src-homology domains) and is involved in several signaling pathways, recruiting cytoplasmic proteins in the vicinity of tyrosine kinase through SH2-phosphotyrosine interaction. The N-terminal SH2 domain of this protein functions as a positive regulator of transformation whereas the C-terminal SH3 domain functions as a negative regulator of transformation. Two alternative transcripts encoding different isoforms with distinct biological activity have been described. [provided by RefSeq, Jul 2008]
- ENST00000300574
- ENSP00000300574
- ENSG00000167193
- ENST00000398970
- ENSP00000381942
- p38
- CRKII
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
hub protein | 0.99 | ||
disease perturbation | 0.95 | ||
transcription factor perturbation | 0.94 | ||
kinase perturbation | 0.93 | ||
pathway | 0.85 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 435.1 (req: < 5)
Gene RIFs: 87 (req: <= 3)
Antibodies: 571 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 435.1 (req: >= 5)
Gene RIFs: 87 (req: > 3)
Antibodies: 571 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 39
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 2
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0